Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:alditol phosphate
go back to main search page
Accession:CHEBI:22297 term browser browse the term
Synonyms:related_synonym: alditol phosphates


show annotations for term's descendants           Sort by:
1,2-dioctanoyl-sn-glycero-3-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO dioctanoylphosphatidic acid results in increased expression of PTGS2 protein CTD PMID:11854442 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
1-octadec-9-enoylglycero-3-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of ACTA2 mRNA
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA]		 CTD PMID:24706986 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation		 ISO
EXP		 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]		 CTD PMID:14769825 PMID:17550345 PMID:20103642 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions ISO ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] CTD PMID:10698703 NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO [Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein CTD PMID:19646460 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446 		JBrowse link
G Bcar1 BCAR1 scaffold protein, Cas family member increases phosphorylation ISO lysophosphatidic acid results in increased phosphorylation of BCAR1 protein CTD PMID:11792571 NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein CTD PMID:23251428 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G C5 complement C5 increases expression ISO lysophosphatidic acid results in increased expression of HC protein CTD PMID:25822713 NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] CTD PMID:23251428 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ccl12 C-C motif chemokine ligand 12 increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of CCL12 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein]		 CTD PMID:25822713 NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780 		JBrowse link
G Ccl28 C-C motif chemokine ligand 28 multiple interactions
increases expression		 ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] CTD PMID:25822713 NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997 		JBrowse link
G Ccn1 cellular communication network factor 1 multiple interactions
increases expression		 ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] CTD PMID:25822713 NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484 		JBrowse link
G Ccn2 cellular communication network factor 2 increases expression
multiple interactions		 EXP
ISO		 lysophosphatidic acid results in increased expression of CCN2 protein
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA]
Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]		 CTD PMID:15200425 PMID:24706986 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734 		JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of COL1A2 mRNA
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA]		 CTD PMID:24706986 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867 		JBrowse link
G Csf1 colony stimulating factor 1 increases expression ISO lysophosphatidic acid results in increased expression of CSF1 protein CTD PMID:25822713 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of CXCL12 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein]		 CTD PMID:25822713 NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of CXCL16 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein]		 CTD PMID:25822713 NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592 		JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 multiple interactions
decreases expression		 ISO lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]
lysophosphatidic acid results in decreased expression of CXCR1 mRNA		 CTD PMID:16224106 NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084 		JBrowse link
G Dgka diacylglycerol kinase, alpha multiple interactions ISO DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] CTD PMID:10913605 NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation		 ISO GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] CTD PMID:23127547 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases phosphorylation		 EXP 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:14769825 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions
decreases expression		 ISO
EXP		 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA]		 CTD PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 More... NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827 		JBrowse link
G Epo erythropoietin multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] CTD PMID:21915944 NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946 		JBrowse link
G Flt4 Fms related receptor tyrosine kinase 4 multiple interactions ISO FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] CTD PMID:18642114 NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770 		JBrowse link
G Gata1 GATA binding protein 1 multiple interactions ISO [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] CTD PMID:21915944 NCBI chr  X:14,529,706...14,537,530
Ensembl chr  X:14,529,702...14,537,530 		JBrowse link
G Gna13 G protein subunit alpha 13 multiple interactions ISO GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] CTD PMID:23127547 NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774 		JBrowse link
G Gypa glycophorin A multiple interactions ISO lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA] CTD PMID:21915944 NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression		 ISO L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein		 CTD PMID:17919812 PMID:22537771 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions
increases phosphorylation		 EXP MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] CTD PMID:20864298 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] CTD PMID:25896349 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 increases secretion ISO lysophosphatidic acid results in increased secretion of IL6 protein CTD PMID:21821728 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il6st interleukin 6 cytokine family signal transducer multiple interactions
increases expression		 ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] CTD PMID:25822713 NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936 		JBrowse link
G Kitlg KIT ligand multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] CTD PMID:21915944 NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214 		JBrowse link
G Kng1 kininogen 1 multiple interactions EXP KNG1 protein inhibits the reaction [[Wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] CTD PMID:10537051 NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555 		JBrowse link
G Lama3 laminin subunit alpha 3 increases expression ISO lysophosphatidic acid results in increased expression of LAMA3 mRNA CTD PMID:15541073 NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353 		JBrowse link
G Lamb3 laminin subunit beta 3 increases expression ISO lysophosphatidic acid results in increased expression of LAMB3 mRNA CTD PMID:15541073 NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405 		JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression ISO lysophosphatidic acid results in increased expression of LAMC2 mRNA CTD PMID:15541073 NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200 		JBrowse link
G Lpar1 lysophosphatidic acid receptor 1 increases response to substance
multiple interactions		 ISO LPAR1 protein results in increased susceptibility to lysophosphatidic acid
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]		 CTD PMID:16224106 PMID:16809448 PMID:25398768 NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895 		JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 multiple interactions ISO Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein CTD PMID:30102254 NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357 		JBrowse link
G Lpar5 lysophosphatidic acid receptor 5 multiple interactions ISO Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein CTD PMID:30102254 NCBI chr 4:157,870,493...157,883,979
Ensembl chr 4:157,881,796...157,882,950 		JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 multiple interactions ISO lysophosphatidic acid binds to and results in increased activity of LPAR6 protein CTD PMID:18297070 NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331 		JBrowse link
G Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 multiple interactions
increases expression		 ISO 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of LYVE1 protein]
lysophosphatidic acid results in increased expression of LYVE1 mRNA; lysophosphatidic acid results in increased expression of LYVE1 protein		 CTD PMID:18642114 NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO
EXP		 Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]		 CTD PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO
EXP		 Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]		 CTD PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mbp myelin basic protein multiple interactions EXP lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] CTD PMID:18594965 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression		 ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] CTD PMID:23127547 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation EXP lysophosphatidic acid results in increased phosphorylation of MTOR protein CTD PMID:14769825 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Myl9 myosin light chain 9 increases phosphorylation
multiple interactions		 ISO lysophosphatidic acid results in increased phosphorylation of MYL9 protein
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]		 CTD PMID:24587105 NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333 		JBrowse link
G Mylk myosin light chain kinase affects response to substance ISO MYLK protein affects the susceptibility to lysophosphatidic acid CTD PMID:10640419 NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein
[[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2		 CTD PMID:25398768 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nppa natriuretic peptide A multiple interactions
increases expression		 EXP Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] CTD PMID:15081308 PMID:25449040 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351 		JBrowse link
G Pak1 p21 (RAC1) activated kinase 1 increases activity
multiple interactions		 EXP lysophosphatidic acid results in increased activity of PAK1 protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; diphenyleneiodonium inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Genistein inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]		 CTD PMID:11855845 NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383 		JBrowse link
G Pdpn podoplanin increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of PDPN mRNA; lysophosphatidic acid results in increased expression of PDPN protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PDPN protein]		 CTD PMID:18642114 NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of PECAM1 protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]		 CTD PMID:18642114 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116 		JBrowse link
G Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha multiple interactions
increases activity		 ISO 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] CTD PMID:10913605 NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
increases expression		 ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Pld1 phospholipase D1 multiple interactions
increases activity		 EXP 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] CTD PMID:11243883 PMID:14769825 NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692 		JBrowse link
G Ppp1r12a protein phosphatase 1, regulatory subunit 12A increases phosphorylation
multiple interactions		 EXP lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein
Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein]		 CTD PMID:25449040 NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425 		JBrowse link
G Prox1 prospero homeobox 1 increases expression
multiple interactions		 ISO lysophosphatidic acid results in increased expression of PROX1 mRNA; lysophosphatidic acid results in increased expression of PROX1 protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]		 CTD PMID:18642114 NCBI chr13:101,669,184...101,719,804
Ensembl chr13:101,669,184...101,711,183 		JBrowse link
G Ptk2 protein tyrosine kinase 2 increases phosphorylation
multiple interactions		 ISO
EXP		 lysophosphatidic acid results in increased phosphorylation of PTK2 protein
[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]
[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]		 CTD PMID:10537051 PMID:11792571 NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783 		JBrowse link
G Ptk2b protein tyrosine kinase 2 beta increases phosphorylation ISO lysophosphatidic acid results in increased phosphorylation of PTK2B protein CTD PMID:11792571 NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282 		JBrowse link
G Rhoa ras homolog family member A increases activity
multiple interactions		 EXP
ISO		 lysophosphatidic acid results in increased activity of RHOA protein
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]		 CTD PMID:15081308 PMID:24587105 NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746 		JBrowse link
G Rhoc ras homolog family member C multiple interactions
increases activity		 ISO Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] CTD PMID:24587105 NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 increases phosphorylation
multiple interactions		 ISO
EXP		 lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein
resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]		 CTD PMID:14769825 PMID:17919812 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Tfrc transferrin receptor multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] CTD PMID:21915944 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions
increases expression		 ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] CTD PMID:25822713 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] CTD PMID:25896349 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression
multiple interactions		 ISO [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein
resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein]		 CTD PMID:17919812 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vegfc vascular endothelial growth factor C increases expression
increases secretion		 ISO lysophosphatidic acid results in increased expression of VEGFC mRNA
lysophosphatidic acid results in increased secretion of VEGFC protein		 CTD PMID:18642114 NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848 		JBrowse link
glycerol 1-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G App amyloid beta precursor protein multiple interactions
decreases abundance		 ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of alpha-glycerophosphoric acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]		 CTD PMID:39172838 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Gk glycerol kinase multiple interactions EXP 1-butyrylglycerol promotes the reaction [[GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid]; [GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid; monoacetin promotes the reaction [[GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid] CTD PMID:9606984 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gpd2 glycerol-3-phosphate dehydrogenase 2 multiple interactions ISO GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of alpha-glycerophosphoric acid] CTD PMID:31974165 NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance		 ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of alpha-glycerophosphoric acid] CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025 		JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 multiple interactions ISO IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] CTD PMID:39172838 NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730 		JBrowse link
G Mapt microtubule-associated protein tau decreases abundance
multiple interactions		 ISO MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid]		 CTD PMID:39172838 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] CTD PMID:39172838 NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO [SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of RUNX2 mRNA CTD PMID:36682590 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167 		JBrowse link
G Sp7 Sp7 transcription factor multiple interactions ISO [SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SP7 mRNA CTD PMID:36682590 NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA CTD PMID:36682590 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162 		JBrowse link
glycerol 2-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA] CTD PMID:25932594 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein] CTD PMID:23111315 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated increases hydrolysis
multiple interactions
increases activity
increases degradation
increases expression		 ISO ALPL protein results in increased hydrolysis of beta-glycerophosphoric acid
[ALPL protein results in increased hydrolysis of beta-glycerophosphoric acid] which results in increased abundance of Phosphates; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein]]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased activity of ALPL protein]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of ALPL mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein]
ALPL protein results in increased degradation of beta-glycerophosphoric acid
[ALPL protein results in increased degradation of beta-glycerophosphoric acid] which results in increased abundance of Phosphates; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA; Diphosphates inhibits the reaction [[ALPL protein results in increased degradation of beta-glycerophosphoric acid] which results in increased abundance of Phosphates]; Diphosphates inhibits the reaction [ALPL protein results in increased degradation of beta-glycerophosphoric acid]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA]		 CTD PMID:17383965 PMID:18500657 PMID:26424790 PMID:26492236 PMID:34575692 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446 		JBrowse link
G Atad2 ATPase family, AAA domain containing 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of ATAD2 mRNA CTD PMID:26424790 NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738 		JBrowse link
G Atad2b ATPase family, AAA domain containing 2B multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ATAD2B mRNA CTD PMID:26424790 NCBI chr 6:27,914,546...28,070,103
Ensembl chr 6:27,912,862...28,067,047 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BECN1 protein CTD PMID:23111315 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions ISO
EXP		 [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP protein; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased secretion of BGLAP protein; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]]		 CTD PMID:17692823 PMID:23111315 PMID:25932594 PMID:26492236 PMID:27028516 More... NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495 		JBrowse link
G Bmp1 bone morphogenetic protein 1 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP1 mRNA CTD PMID:15994055 NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776 		JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions EXP
ISO		 [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]		 CTD PMID:15994055 PMID:22940495 PMID:23111315 PMID:26492236 PMID:27387537 NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397 		JBrowse link
G Bmp3 bone morphogenetic protein 3 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP3 mRNA CTD PMID:15994055 NCBI chr14:10,712,489...10,737,153
Ensembl chr14:10,712,489...10,737,153 		JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP7 mRNA CTD PMID:15994055 NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788 		JBrowse link
G Bmpr1a bone morphogenetic protein receptor type 1A multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] CTD PMID:27387537 NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of CEBPA protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA		 CTD PMID:14505802 PMID:25932594 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412 		JBrowse link
G Chaf1b chromatin assembly factor 1 subunit B multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of CHAF1B mRNA CTD PMID:26424790 NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070 		JBrowse link
G Cited1 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA] CTD PMID:28189605 NCBI chr  X:67,350,376...67,355,072
Ensembl chr  X:67,350,373...67,355,162 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA]		 CTD PMID:31935364 PMID:34562440 PMID:34575692 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA] CTD PMID:35738543 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Dmp1 dentin matrix acidic phosphoprotein 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA] CTD PMID:25932594 PMID:35738543 NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323 		JBrowse link
G Dpf1 double PHD fingers 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPF1 mRNA CTD PMID:26424790 NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950 		JBrowse link
G Dppa2 developmental pluripotency-associated 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPPA2 mRNA CTD PMID:28189605 NCBI chr11:52,549,024...52,556,740
Ensembl chr11:52,549,651...52,556,740 		JBrowse link
G Dspp dentin sialophosphoprotein multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA] CTD PMID:35738543 NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672 		JBrowse link
G Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 increases expression
increases activity
multiple interactions		 ISO beta-glycerophosphoric acid results in increased expression of ENPP1 mRNA
beta-glycerophosphoric acid results in increased activity of ENPP1 protein
Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased activity of ENPP1 protein]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of ENPP1 mRNA]		 CTD PMID:18500657 NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715 		JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of EZH1 mRNA CTD PMID:26424790 NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921 		JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 protein; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] CTD PMID:26424790 NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362 		JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA] CTD PMID:25062436 PMID:25932594 PMID:32473317 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578 		JBrowse link
G Fancl FA complementation group L multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA CTD PMID:26424790 NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255 		JBrowse link
G Fgf23 fibroblast growth factor 23 increases expression ISO beta-glycerophosphoric acid results in increased expression of FGF23 mRNA CTD PMID:15542045 NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]] CTD PMID:27028516 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gdf10 growth differentiation factor 10 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of GDF10 mRNA CTD PMID:15994055 NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343 		JBrowse link
G Gpc3 glypican 3 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA] CTD PMID:28189605 NCBI chr  X:131,868,986...132,236,824
Ensembl chr  X:131,868,990...132,236,798 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of H2AX mRNA CTD PMID:26424790 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239 		JBrowse link
G Hand2 heart and neural crest derivatives expressed 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA] CTD PMID:28189605 NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891 		JBrowse link
G Hells helicase, lymphoid specific multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HELLS mRNA CTD PMID:26424790 NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844 		JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB1 mRNA CTD PMID:26424790 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565 		JBrowse link
G Hmgb2 high mobility group box 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB2 mRNA CTD PMID:26424790 NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
Ensembl chr 1:32,710,658...32,713,140 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]] CTD PMID:27028516 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Ibsp integrin-binding sialoprotein multiple interactions EXP
ISO		 [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA]		 CTD PMID:26492236 PMID:27028516 NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693 		JBrowse link
G Ins1 insulin 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA CTD PMID:25062436 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]		 CTD PMID:25932594 PMID:32473317 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Msx2 msh homeobox 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA] CTD PMID:28189605 NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; MTOR protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein] CTD PMID:23111315 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Nog noggin multiple interactions EXP NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] CTD PMID:27387537 NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA] CTD PMID:25932594 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nsd2 nuclear receptor binding SET domain protein 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of NSD2 mRNA CTD PMID:26424790 NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641 		JBrowse link
G Parg poly (ADP-ribose) glycohydrolase multiple interactions ISO PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein]; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA] CTD PMID:22940495 NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of PARP1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of PARP1 mRNA]
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein modified form; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein]; PARP1 mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]		 CTD PMID:22940495 PMID:26492236 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Phex phosphate regulating endopeptidase X-linked increases expression
multiple interactions		 ISO beta-glycerophosphoric acid results in increased expression of PHEX mRNA
Foscarnet inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA]		 CTD PMID:18500657 NCBI chr  X:37,607,553...37,856,183
Ensembl chr  X:37,610,760...37,854,469 		JBrowse link
G Phf2 PHD finger protein 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PHF2 mRNA CTD PMID:26424790 NCBI chr17:15,783,221...15,851,209
Ensembl chr17:15,781,864...15,851,208 		JBrowse link
G Plin1 perilipin 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]		 CTD PMID:25932594 PMID:32473317 NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of POU5F1 mRNA CTD PMID:28189605 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]]; Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA] CTD PMID:14505802 PMID:25932594 PMID:32473317 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Pth1r parathyroid hormone 1 receptor multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PTH1R mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PTH1R mRNA] CTD PMID:28189605 NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; MTOR protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein] CTD PMID:23111315 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of RPTOR protein CTD PMID:23111315 NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions
increases expression		 ISO
EXP		 [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; bisphenol A inhibits the reaction [beta-glycerophosphoric acid results in increased expression of RUNX2 protein]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]; PARP1 mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]		 CTD PMID:17692823 PMID:22940495 PMID:23111315 PMID:26424790 PMID:26492236 More... NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167 		JBrowse link
G Satb2 SATB homeobox 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA] CTD PMID:26424790 NCBI chr 9:58,348,027...58,534,256
Ensembl chr 9:58,350,246...58,530,707 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA]]; Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA] CTD PMID:14505802 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Smad1 SMAD family member 1 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD1 mRNA] CTD PMID:26492236 NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651 		JBrowse link
G Smad4 SMAD family member 4 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD4 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD4 mRNA] CTD PMID:26492236 NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438 		JBrowse link
G Smad5 SMAD family member 5 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD5 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD5 mRNA] CTD PMID:26492236 NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634 		JBrowse link
G Smad9 SMAD family member 9 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD9 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD9 mRNA] CTD PMID:26492236 NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SOX2 mRNA CTD PMID:28189605 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SOX9 mRNA CTD PMID:26424790 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994 		JBrowse link
G Sp7 Sp7 transcription factor multiple interactions
increases expression		 ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]
beta-glycerophosphoric acid results in increased expression of SP7 protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SP7 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; bisphenol A inhibits the reaction [beta-glycerophosphoric acid results in increased expression of SP7 protein]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]		 CTD PMID:22940495 PMID:25062436 PMID:25932594 PMID:26492236 PMID:32324263 More... NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847 		JBrowse link
G Sparc secreted protein acidic and cysteine rich multiple interactions ISO [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein CTD PMID:17692823 NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPP1 protein; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SPP1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SPP1 mRNA]		 CTD PMID:17692823 PMID:22940495 PMID:26492236 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the expression of SQSTM1 protein CTD PMID:23111315 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA]] CTD PMID:14505802 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:25932594 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Stc1 stanniocalcin 1 decreases expression EXP beta-glycerophosphoric acid results in decreased expression of STC1 mRNA CTD PMID:17438129 NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264 		JBrowse link
G Suv39h1 SUV39H1 histone lysine methyltransferase multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H1 mRNA CTD PMID:26424790 NCBI chr  X:14,421,028...14,433,993
Ensembl chr  X:14,421,109...14,433,982 		JBrowse link
G Suv39h1-ps1 SUV39H1 histone lysine methyltransferase, pseudogene 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H1 mRNA CTD PMID:26424790 NCBI chr  X:141,792,589...141,795,257 JBrowse link
G Suv39h2 SUV39H2 histone lysine methyltransferase multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H2 mRNA CTD PMID:26424790 NCBI chr17:74,756,290...74,775,332
Ensembl chr17:74,756,306...74,775,332 		JBrowse link
G Tafazzin tafazzin, phospholipid-lysophospholipid transacylase multiple interactions ISO [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of TAFAZZIN mRNA CTD PMID:17692823 NCBI chr  X:152,065,539...152,076,178
Ensembl chr  X:152,065,609...152,074,001 		JBrowse link
G Tcf19 transcription factor 19 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of TCF19 mRNA CTD PMID:26424790 NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271 		JBrowse link
G Tcf20 transcription factor 20 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TCF20 mRNA CTD PMID:26424790 NCBI chr 7:113,953,449...114,104,166
Ensembl chr 7:113,954,089...114,051,839 		JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] CTD PMID:26424790 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of and results in increased secretion of TNFSF11 protein CTD PMID:32156525 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Uhrf1 ubiquitin-like with PHD and ring finger domains 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of UHRF1 mRNA CTD PMID:26424790 NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631 		JBrowse link
G Uhrf2 ubiquitin like with PHD and ring finger domains 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of UHRF2 mRNA CTD PMID:26424790 NCBI chr 1:227,814,639...227,877,907
Ensembl chr 1:227,814,963...227,877,904 		JBrowse link
G Vcl vinculin multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein; Hydroxychloroquine inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein] CTD PMID:28975700 NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606 		JBrowse link
G Wnt1 Wnt family member 1 multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of WNT1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of WNT1 mRNA] CTD PMID:35738543 NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651 		JBrowse link
G Wnt11 Wnt family member 11 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of WNT11 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of WNT11 mRNA] CTD PMID:28189605 NCBI chr 1:153,134,503...153,154,294
Ensembl chr 1:153,138,197...153,154,294 		JBrowse link
lysophosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ddr1 discoidin domain receptor tyrosine kinase 1 ISO lysophosphatidic acid increased expression of Ddr1 in 3T3 and GD25 cells RGD PMID:28199848 RGD:151347403 NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468 		JBrowse link
G Prkd1 protein kinase D1 increases phosphorylation EXP LPA increases phosphorylation of Prkd1 protein in neonatal ventricular myocytes RGD PMID:16648482 RGD:243065275 NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19874
    role 19844
      application 19689
        NMR chemical shift reference compound 18065
          phosphoric acid 13926
            phosphoric acid derivative 13835
              organic phosphate 13834
                carbohydrate phosphate 1965
                  alditol phosphate 158
                    alditol 1-phosphate + 0
                    alditol 3-phosphate + 0
                    alditol 4-phosphate + 0
                    alditol 5-phosphate + 0
                    alditol 6-phosphate + 0
                    glycerol phosphate + 158
                    hexitol phosphate + 0
                    pentitol phosphate + 0
                    tetritol phosphate + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19874
    subatomic particle 19872
      composite particle 19872
        hadron 19872
          baryon 19872
            nucleon 19872
              atomic nucleus 19872
                atom 19872
                  main group element atom 19811
                    p-block element atom 19811
                      chalcogen 19563
                        oxygen atom 19535
                          oxygen molecular entity 19535
                            hydroxides 19341
                              oxoacid 18777
                                pnictogen oxoacid 14974
                                  phosphorus oxoacid 14577
                                    phosphoric acids 13926
                                      phosphoric acid 13926
                                        phosphoric acid derivative 13835
                                          phosphate 13834
                                            organic phosphate 13834
                                              carbohydrate phosphate 1965
                                                alditol phosphate 158
                                                  alditol 1-phosphate + 0
                                                  alditol 3-phosphate + 0
                                                  alditol 4-phosphate + 0
                                                  alditol 5-phosphate + 0
                                                  alditol 6-phosphate + 0
                                                  glycerol phosphate + 158
                                                  hexitol phosphate + 0
                                                  pentitol phosphate + 0
                                                  tetritol phosphate + 0
paths to the root